Tenet Healthcare Corporation

Tenet Healthcare Corporation (THC) Market Cap

Tenet Healthcare Corporation has a market capitalization of $13.96B.

Price: $162.06

ā–² 0.69 (0.43%)

Market Cap: 13.96B

NYSE Ā· time unavailable

CEO: Saumya Sutaria

Sector: Healthcare

Industry: Medical - Care Facilities

IPO Date: 1980-03-17

Website: https://www.tenethealth.com

Tenet Healthcare Corporation (THC) - Company Information

Market Cap: 13.96B|Sector: Healthcare

Company Profile

Tenet Healthcare Corporation operates as a diversified healthcare services company. The company operates in three segments: Hospital Operations and Other, Ambulatory Care, and Conifer. Its general hospitals offer acute care services, operating and recovery rooms, radiology and respiratory therapy services, clinical laboratories, and pharmacies. The company also provides intensive and critical care, and coronary care units; cardiovascular, digestive disease, neurosciences, musculoskeletal, and obstetrics services; outpatient services, including physical therapy; cardiothoracic surgery, complex spinal surgery, neonatal intensive care, and neurosurgery services; quaternary care services in heart and kidney transplants; and limb-salvaging vascular procedure, acute level 1 trauma, intravascular stroke care, minimally invasive cardiac valve replacement, imaging, and telemedicine access services. In addition, it operates ambulatory surgery and urgent care centers, imaging centers, surgical hospitals, off-campus emergency departments, and micro-hospitals; and offers healthcare business process services in the areas of hospital and physician revenue cycle management, patient communications and engagement support, and value-based care solutions to hospitals, health systems, physician practices, employers, and other customers. As of February 09, 2022, the company operated 60 hospitals; and approximately 550 other healthcare facilities, including surgical hospitals, ambulatory surgery centers, urgent care and imaging centers, and other care sites and clinics. Tenet Healthcare Corporation was incorporated in 1975 and is headquartered in Dallas, Texas.

Analyst Sentiment

92%
Strong Buy

From 22 Active Polls

1Y Forecast: $259.50

ā–² +60.1% Potential Upside

Consensus Target Metrics

Low Bound

$210

Median

$263

High Bound

$288

Average

$260

Price & Moving Averages

Loading chart...

šŸŽÆ Wall Street Analyst Intelligence Report

1-Year structural target targets, chart projections, and sentiment maps.

Average 1Y Target
$259.50
ā–² +60.13% Upside
Low Target
$210.00
30% Risk
Median Target
$262.50
62% Mid
High Target
$288.00
78% Max
Consensus
Buy
26 / 32 Buys

Consensus Trend Projection

Trailing closures vs. 12-month metrics map.

Analyst Vote Distribution

Aggregate institutional coverage sentiment weights.

šŸ“Š Historical Valuation Multiples

Real-time Trailing Twelve Month (TTM) momentum side-by-side with discrete quarterly metrics.

Fiscal QuarterTTMQ1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024
Period EndingTrailing 12MMar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024
Market Cap ($M)13,95916,38017,34217,85816,04012,67612,00515,90012,966
Enterprise Value ($M)24,20126,62227,63028,07026,59022,84722,15924,67722,957
Price to Earnings Ratio (P/E)8.265.8311.6913.0513.927.819.448.4212.52
Price/Earnings-to-Growth Ratio (PEG)——2.6038.2315.152.62—22.62—
Price to Sales Ratio (P/S)0.653.053.143.383.042.432.373.102.54
Price to Book Ratio (P/B)2.923.404.114.454.283.032.884.153.73
Price to Free Cash Flow Ratio (P/FCF)4.1711.2147.2522.9521.5919.74-18.1618.9521.54
Enterprise Value to Sales (EV/Sales)—4.965.005.315.044.374.374.824.50
Enterprise Value to EBITDA (EV/EBITDA)5.5023.9625.1224.7125.1819.4421.0818.5123.00
Debt to Equity Ratio2.332.743.123.293.513.153.163.363.70

⚔ THC Growth Runway Model

Standard long term linear growth fade

Multi-Stage Discounted Cash Flow Sandbox

Market Price$162.06
Intrinsic Value$298.37
Market Alignment
Undervalued by 84.1%relative to calculated intrinsic value
9.00%
Exp: 3%3%
i

Growth runway slowdown

This value provides a time window for the growth rate to decline beyond Stage 1 toward the terminal rate. Longer windows are most useful for companies with high growth starting conditions or strong competitive advantages. This option stretches out the growth rate slowdown across 5, 10, or 15-year steps. A high-growth starting condition (exceeding a 25% initial growth rate) automatically applies a curve decay to simulate realistic, rapid market saturation.
i

Terminal growth rate

With long-term inflation between 3-5%, revenue must grow by that baseline to maintain flat real-world market share. This value sets the permanent terminal growth rate to factor into the valuation beyond the growth slowdown runway toward maturity.

3-Stage Financial Runway Horizon

🧠 Perpetuity Horizon Engine (Stage 3: Post-2035)

Terminal FCF Base$2.87B
Perpetuity TV Value$53.98B
Discounted TV (PV)$22.80B
TV Weighting %59.4%
āš ļø
Financial Model Disclaimer & Risk Disclosure: This interactive scenario simulator is an educational sandbox provided strictly for informational and analytical research purposes. Core historical financial statements and consensus estimates are sourced directly via Financial Modeling Prep (FMP). All downstream outputs are entirely deterministic, hypothetical projections generated by combining automated mathematical formulas (including linear interpolation and Gaussian bell-curve decay models) with user-selected variables and third-party financial data inputs. Users assume all liability for trading decisions executed based on these sandbox calculations.

šŸ“˜ Full Research Report

ā„¹ļø

AI-Generated Research: This report is for informational purposes only.

šŸ“˜ TENET HEALTHCARE CORP (THC) — Investment Overview

🧩 Business Model Overview

Tenet Healthcare operates a network of acute-care hospitals and related outpatient and behavioral-health services, delivering care to commercially insured, Medicare, and Medicaid patients. The value chain centers on (1) facility-based clinical capabilities, (2) physician and care team utilization across service lines (e.g., emergency, surgical, specialty), (3) payer contracting and reimbursement management, and (4) revenue cycle execution (coding, billing, denials management, and collections).

Patient volumes and service-line mix drive utilization of fixed hospital capacity, while contract terms with payers and charge capture/reimbursement realization determine net revenue per case. Tenet’s ecosystem—hospital operations plus outpatient and specialty offerings—supports continuity of care and improves referrals and downstream service utilization within its footprint.

šŸ’° Revenue Streams & Monetisation Model

Revenue is primarily generated through patient services billed on a combination of fee-for-service and contractual rates, with growing exposure to value-based arrangements where applicable. Key monetisation components include:

  • Inpatient services: admissions and procedure mix across medical, surgical, and intensive care—often the largest revenue contributor.
  • Emergency and acute services: capture high-acuity demand and funnel patients into inpatient and specialty care.
  • Outpatient and ambulatory services: imaging, diagnostics, outpatient surgery, and specialty clinics that extend the revenue base beyond inpatient capacity.
  • Behavioral health services (where present in the network): adds differentiated demand patterns and service-line diversification.

Margin structure is shaped by staffing efficiency, labor and supply cost intensity, payer reimbursement levels, and revenue cycle performance. Because hospital fixed costs are meaningful, operating leverage can emerge when volumes and acuity align with capacity, while reimbursement pressure or labor inflation compresses margins.

🧠 Competitive Advantages & Market Positioning

Tenet’s competitive position is anchored less in patents and more in operating and market-structure barriers typical of healthcare delivery. The moat is best characterized as an integrated ecosystem plus scale-driven cost advantages, supported by high switching frictions for payers and referral patterns.

  • Integrated ecosystem (referral and continuity advantage): Multi-service hospital systems can retain patients through referrals across emergency, inpatient, outpatient, and specialty pathways. This increases the ā€œshare of careā€ within the footprint.
  • Scale and purchasing leverage (cost advantage): Consolidated operations can improve procurement terms, labor scheduling discipline, and system-wide standardization in clinical and administrative processes.
  • Regulatory and operational barriers (high barrier to entry): Licensing, compliance, quality requirements, and the capital intensity of building/operating acute-care capacity limit new entrants in many geographies.
  • Payer contracting relationships (switching friction): Payers negotiate within established networks; network inclusion is influenced by historical performance, geographic access, and clinical outcomes—raising the cost to rapidly replace a high-quality provider.

Competitive benchmarking (primary peers):

  • HCA Healthcare: similarly large-scale hospital operator with a broad U.S. presence and strong scale economics. Compared with Tenet, HCA’s geographic mix and system density can differ, affecting payer negotiations and referral dynamics.
  • Universal Health Services (UHS): more pronounced in behavioral health and specialty services alongside acute care. UHS’s emphasis can shape different payer and referral relationships than Tenet’s broader acute-care footprint.
  • Community Health Systems (CYH): historically more exposed to smaller markets and facility-level idiosyncrasies. Tenet’s portfolio mix and execution can influence resilience to reimbursement pressure and labor cost volatility.

Across these rivals, the industry’s ā€œwinningā€ factor remains operational discipline and local market positioning—particularly the ability to sustain quality, secure payer contracts, and manage labor and denials/reimbursement performance—rather than technology-led disruption alone.

šŸš€ Multi-Year Growth Drivers

  • Industry demand tailwinds: Aging demographics and chronic disease prevalence increase utilization of acute and outpatient services, supporting long-run case volume.
  • Service-line expansion and mix shift: Growth can come from scaling higher-acuity and specialty procedures where clinical expertise and care pathways reinforce referrals within the network.
  • Shift toward accountable care/value-based models: Value-based reimbursement can improve economics for organizations that invest in care management, quality outcomes, and cost control—particularly through population health initiatives tied to inpatient discharge and outpatient follow-through.
  • Outpatient substitution with system depth: As care migrates to ambulatory settings, integrated hospital-outpatient systems can monetize demand across the ā€œsite of careā€ continuum, protecting share.
  • Operational improvements as a compounding engine: Sustained enhancements in revenue cycle, coding accuracy, payer dispute management, and workforce productivity can translate to margin stability over a full cycle.

Over a 5–10 year horizon, the TAM is influenced by healthcare utilization growth and by payment reform complexity. Providers that execute through reimbursement variability and care-delivery redesign tend to compound performance through both volume and margin discipline.

⚠ Risk Factors to Monitor

  • Payer reimbursement pressure: Managed care rate pressure, denials, and regulatory-driven reimbursement changes can reduce net revenue per case.
  • Medicare/Medicaid policy changes: Shifts in payment methodology, acuity definitions, or program eligibility can alter economics across a meaningful portion of the patient mix.
  • Labor and supply cost inflation: Hospitals remain highly labor-intensive; wage inflation and staffing shortages can pressure operating margins without offsetting rate increases.
  • Regulatory compliance and enforcement: Health IT requirements, coding compliance, and quality metrics expose the company to audit risk and potential penalties.
  • Capital intensity and balance sheet considerations: Facility upgrades, IT infrastructure, and compliance investments require sustained capital access; adverse credit conditions can constrain flexibility.
  • Utilization and acuity volatility: Cyclicality in elective procedures and shifts in patient acuity can create operating leverage swings.
  • Cybersecurity and operational resilience: Disruptions to billing, clinical operations, or data integrity can create direct and indirect financial impacts.

šŸ“Š Valuation & Market View

The market typically values healthcare delivery companies using EV/EBITDA-type frameworks and monitors drivers tied to cash generation: operating margin durability, reimbursement trends, admission trends and acuity, labor productivity, and revenue cycle performance. Because hospital economics are sensitive to cost and payer terms, valuation bands often respond to perceived trajectory in (1) sustainable net revenue per case, (2) controllable expense growth, and (3) capital allocation capacity (capex and debt service).

In a broader context, investors also weigh the defensibility of local market share, the quality of payer relationships, and whether the company can transition successfully across reimbursement models without margin deterioration.

šŸ” Investment Takeaway

Tenet Healthcare’s long-term investment case rests on enduring barriers to entry in acute-care delivery, an integrated care ecosystem that supports referral and continuity, and scale-enabled operational and cost advantages. While reimbursement, labor, and regulatory policy represent persistent cyclical and structural risks, the company’s competitive durability is expected to come from execution—particularly revenue realization, revenue cycle rigor, and disciplined operations—rather than from single-product or patent-like protection.


⚠ AI-generated — informational only. Validate using filings before investing.

šŸ“° Market News & Coverage

15 Stories Available

Real-time institutional reporting and market updates for THC.

zacks.com•2026-06-04

Tenet Healthcare (THC) Stock Dips While Market Gains: Key Facts

Tenet Healthcare (THC) closed the most recent trading day at $161.37, moving 2.11% from the previous trading session.

zacks.com•2026-06-04

Tenet Healthcare Corporation (THC) Is a Trending Stock: Facts to Know Before Betting on It

Tenet (THC) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

seekingalpha.com•2026-05-26

Tenet Healthcare Corporation's Regulatory Woes Don't Put It In The ER

Tenet Healthcare Corporation remains a compelling Buy, supported by strong financial performance and deeply discounted valuation versus peers. Despite a recent 22.7% stock decline and regulatory headwinds, THC's Ambulatory Care segment shows resilience, with revenue up from $1.19B to $1.32B and profit growth. Management guides for 2026 revenue of $21.5B–$22.3B, EBITDA of $4.485B–$4.785B, and adjusted net profits of $1.425B–$1.625B.

zacks.com•2026-05-26

Here's Why Tenet Healthcare (THC) is a Strong Growth Stock

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

zacks.com•2026-05-25

Here's Why Tenet Healthcare (THC) is a Strong Value Stock

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

feeds.benzinga.com•2026-05-24

NIO, Intuit, And Reddit Are Among Top 10 Large-Cap Losers Last Week (May 18-May 22): Are The Others In Your Portfolio?

Large-cap laggards last week were pressured by weak guidance, regulatory concerns, rising bond yields and competitive threats, with technology, EV, healthcare and data center-linked stocks leading the declines.

zacks.com•2026-05-22

Is Tenet (THC) a Solid Growth Stock? 3 Reasons to Think "Yes"

Tenet (THC) is well positioned to outperform the market, as it exhibits above-average growth in financials.

gurufocus.com•2026-05-21

Tenet Healthcare Corp (THC) Stock Down 5.0% but Still Overvalued -- GF Score: 79/100

On May 21, 2026, Tenet Healthcare Corp (THC) shares fell 5.0% to a current price of $178.00. This decline comes in the context of a 52-week range of $146.60 to

zacks.com•2026-05-21

Investors Heavily Search Tenet Healthcare Corporation (THC): Here is What You Need to Know

Tenet (THC) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

zacks.com•2026-05-20

Here's Why Tenet Healthcare (THC) is a Strong Momentum Stock

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

zacks.com•2026-05-19

Is Tenet (THC) a Buy as Wall Street Analysts Look Optimistic?

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?

zacks.com•2026-05-18

Wall Street Analysts Think Tenet (THC) Could Surge 26.16%: Read This Before Placing a Bet

The mean of analysts' price targets for Tenet (THC) points to a 26.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

zacks.com•2026-05-15

Is Tenet Healthcare (THC) Stock Undervalued Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

seekingalpha.com•2026-05-13

Tenet Healthcare Corporation (THC) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Tenet Healthcare Corporation (THC) Presents at Bank of America Global Healthcare Conference 2026 Transcript

zacks.com•2026-05-08

Why Tenet Healthcare (THC) is a Top Value Stock for the Long-Term

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

šŸ“Š AI Financial Analysis

Powered by StockMarketInfo
Earnings Data: Q Ending 2026-03-31

"Q1 2026 results show strong top-line and profit improvement: Revenue was $5.368B (QoQ -2.9%, YoY +2.8%). Net Income rose to $906M (QoQ +144.4%, YoY +123.0%), with EPS of $8.09 (diluted $8.01). Profitability improved materially: gross margin expanded to ~59.5% from ~41.5% in Q4 and ~42.0% in Q1 last year, while operating margin increased to ~24.1% vs ~15.4% in Q4 and ~18.1% a year ago. Net margin also jumped to ~16.9% from ~6.7% in Q4 and ~7.8% in Q1 last year, indicating strong cost and/or pricing leverage. Cash flow quality was solid in the quarter. Operating cash flow (OCF) was $1.641B and free cash flow (FCF) was $1.461B, supporting aggressive capital returns: buybacks were $318M in the quarter, and the company ended with $2.967B cash. Balance sheet resilience looks mixed by structure: total assets grew to $31.2B (from $29.7B in Q4), but equity declined sequentially to $4.8B (from $8.97B), while total liabilities increased to $22.35B. Importantly, net debt turned strongly favorable at -$2.886B (net cash) versus net debt of $10.288B at Q4, improving financial flexibility. Total shareholder returns were likely strong given price momentum (+63% 1-year). With no dividend payments reported, returns appear primarily driven by buybacks and share price appreciation."

Revenue Growth

Neutral

Revenue was $5.368B in Q1 2026 (QoQ -2.9%; YoY +2.8%), showing modest YoY growth but a slight sequential pullback.

Profitability

Strong

Net income jumped to $906M (QoQ +144.4%; YoY +123.0%). Margins expanded sharply: gross ~59.5% vs ~41.5% in Q4 and ~42.0% YoY; net margin ~16.9% vs ~6.7% QoQ and ~7.8% YoY.

Cash Flow Quality

Good

FCF was strong at $1.461B (OCF $1.641B). Buybacks of $318M supported shareholder returns; dividends were $0.

Leverage & Balance Sheet

Positive

Balance sheet flexibility improved materially: net debt was -$2.886B (net cash) vs +$10.288B at Q4. However, equity fell sequentially to $4.814B, indicating leverage/valuation movements or capital structure effects.

Shareholder Returns

Strong

High price momentum (+63.27% 1y_change) plus quarterly buybacks ($318M) suggests strong total return. Dividend yield is 0.

Analyst Sentiment & Valuation

Neutral

Consensus target around $268.75 vs a current price $196.64 implies ~+36.6% upside, but valuation multiples (e.g., low reported P/E in the ratio set) and recent margin volatility temper confidence.

Disclaimer:This analysis is AI-generated for informational purposes only. Accuracy is not guaranteed and this does not constitute financial advice.

Fundamentals Overview

Loading fundamentals overview...

Tenet started 2026 with broad-based operating outperformance: $5.4B net operating revenues, $1.16B adjusted EBITDA, and 21.6% margin, with both segments tracking ahead of full-year guidance pace (USPI 36.7% margin; Hospital 16.7%). The quarter’s headline risks—exchange enrollment declines, weather disruptions, and respiratory admissions collapse (respiratory admissions -41% YoY)—were largely offset by disciplined cost flexing and automation initiatives aimed at length-of-stay, throughput, and back-office productivity (including AI-enabled analytics and EMR-integrated tools). Exchange revenues were ~6% of consolidated revenues and down ~9% YoY; same-store exchange admissions fell ~10% YoY, contributing to ~$250M full-year exchange impact guidance (~20% volume reduction), with Q1 described as lower than a simple linear ramp. Capital remained a clear support: $978M adjusted free cash flow in Q1, $2.97B cash with no revolver borrowings, and $318M of repurchases. Guidance was reaffirmed, and management reiterated confidence in achieving ~10% midpoint adjusted EBITDA growth (after normalization and excluding premium tax credit expiration).

AI IconGrowth Catalysts

  • USPI: double-digit same-store volume growth in total joint replacements within ASCs; same-facility system-wide revenues +5.3% YoY and net revenue per case +5.6%
  • Hospital: automation/process automation aimed at length-of-stay and capacity controls; AI-related capabilities across hospitals, physician practices, and global business center to improve throughput
  • Hospital: third-party EMR integrated solutions (ambient scribe, automated discharge summaries, autonomous professional fee coding) plus back-office AI automation to consolidate third-party spend
  • USPI: de novo expansion—commenced patient care at 3 de novo centers (half of targeted full-year spend completed in Q1)
  • USPI: high-acuity service line mix supporting stronger case mix/CMI trajectory (CMI noted down temporarily due to respiratory impact)

Business Development

  • USPI acquisitions: invested $125 million in Q1 to acquire 7 ASCs
  • De novo centers: patient care initiated at 3 de novos (half of targeted full-year spend completed)
  • Partnership references (MSO/health-system contributors to USPI quality improvement agenda): Baylor; Memorial Hermann
  • Conifer transaction: referenced as completed; onetime ~$40 million favorable revenue adjustment recognized in Q1

AI IconFinancial Highlights

  • Net operating revenues: $5.4B; consolidated adjusted EBITDA: $1.16B; adjusted EBITDA margin: 21.6% (outperformed previously provided expectations)
  • USPI: adjusted EBITDA $484M; adjusted EBITDA margin 36.7%; USPI adjusted EBITDA 6% growth vs Q1 2025; 22% of full-year 2026 adjusted EBITDA guidance achieved by quarter
  • Hospital: adjusted EBITDA $678M; adjusted EBITDA margin 16.7%; 27.5% of full-year 2026 adjusted EBITDA guidance achieved by quarter; outperformance tied to disciplined expense management and growth initiatives
  • Hospital admissions: same-hospital inpatient adjusted admissions +0.6% YoY; respiratory admissions down 41% YoY, cited as a 90 bps reduction in admissions growth
  • Exchange dynamics: exchange revenues ~6% of consolidated revenues in Q1 2026, down 9% YoY; same-store exchange admissions about 10% lower vs Q1 2025
  • One-time items: onetime ~$40M favorable revenue adjustment in Q1 related to completed Conifer transaction (included in original guidance; not included in revenue per adjusted admission calculations)
  • Supplemental Medicaid: $304M in Q1 2026, consistent with guidance; no out-of-period supplemental Medicaid benefit from prior years in Q1 2026
  • Cost flexibility: salary, wages & benefits were 40.5% of net revenues, consistent YoY despite net revenue headwinds
  • Capital return: repurchased 1.35M shares for $318M in Q1 2026
  • Guidance framework: reaffirmed full-year 2026 outlook; adjusted EBITDA expected to grow ~10% at midpoint after normalizing Q1 2025 non-recurring items and excluding expiration of premium tax credits headwind

AI IconCapital Funding

  • Adjusted free cash flow: $978M in Q1 2026
  • Cash on hand (Mar 31, 2026): $2.97B; no borrowings outstanding under line of credit
  • Debt: no significant maturities until late 2027
  • Share repurchases: $318M in Q1; management expects continued deployment over the balance of 2026
  • Full-year cash flow outlook: adjusted free cash flow after NCI range $1.6B–$1.83B
  • Tax payments: expects ~$150M tax payments for the Conifer transaction in 2026; excluding these tax payments, midpoint ~$1.865B adjusted free cash flow after NCI

AI IconStrategy & Ops

  • Expense initiatives from Q4 2025: execution benefits recognized in Q1 2026
  • Capacity/throughput: process automation to address length of stay and capacity controls to improve clinical throughput
  • Governance for scaling: AI/agent tools structured with governance that green-lights rapid scaling or red-lights shutdowns
  • Hospital tech pilots expanded: ambient scribe; automated discharge summaries; autonomous professional fee coding (pilot programs referenced)
  • AI productivity gains: Conifer analytics team productivity nearly doubled (or more)
  • Q1 disruptions managed: two major winter storms and vendor cyber-attack uncertainty; procedures rescheduled to lessen overall impact
  • USPI growth capex/M&A: $125M invested in Q1 for 7 ASC acquisitions; ongoing pipeline of assets interested in joining USPI this year

AI IconMarket Outlook

  • Full-year 2026 guidance reaffirmed (no adjustment despite Q1 outperformance); excluding contributions from potential increases in supplemental Medicaid programs not yet approved/finalized by CMS
  • Q2 2026: expect consolidated adjusted EBITDA equal to 24%–25% of full-year at the midpoint; USPI EBITDA also 24%–25% of full-year USPI EBITDA at the midpoint
  • Exchange impact assumption: Q1 exchange impact was lower than linear ramp; management reiterated full-year exchange impact guidance range of ~$250M and ~20% reduction in volumes (explained as consistent vs first quarter dynamics and grace period effects)

AI IconRisks & Headwinds

  • Exchange enrollment uncertainty (Medicaid and exchange); payer mix shifts and seasonal effects impacting demand
  • Exchange coverage decline: same-store exchange admissions down ~10% YoY; exchange revenues down ~9% YoY
  • Uncompensated care stepped up, with management attributing some portion to expiration of exchange subsidies (no meaningful change in denials/disputes trend in Q1 vs prior year, though levels remain 'too high')
  • Respiratory volume headwind: respiratory admissions down 41% YoY in Q1; cited as 90 bps reduction in admissions growth; implied margin headwind but overcame via cost flexing
  • External disruption risk: winter storms and uncertainty from vendor cyber attacks caused procedure rescheduling and operational variability
  • Regulatory uncertainty: outpatient rule awaited; no proprietary CMS/HHS IPPS clarity provided beyond commentary

Q&A: Analyst Interest

  • Exchange denials/uncompensated care: Management stated payer disputes/denials remain 'high' versus pre-pandemic but saw no meaningful change in net denials/disputes in Q1 relative to last year. They noted the slight increase in uncompensated care likely relates to expiration of exchange subsidies, but they did not see an additional material shift this quarter.
  • Length-of-stay and throughput run-rate: Management tied LOS improvement to bed availability required by their high-acuity strategy. They emphasized that maintaining throughput/capacity is necessary to 'say yes' to high-acuity needs, and that LOS management is now 'better than even breakeven' due to both traditional management and newer tools, supporting capacity avoidance.
  • Medicaid vs exchange drivers of trends: Management said Medicaid is 'down a little' and pointed to California as an example, suggesting disenrollment/lack of renewal among populations possibly not qualified under federal regulations. They also referenced border communities: hesitation/tone affecting outpatient primary care, while hospital impact remained minimal due to treating sick patients.

Sentiment: POSITIVE

Note: This summary was synthesized by AI from the THC Q1 2026 (ended March 31, 2026) earnings transcript. Financial data is complex; please verify all metrics against official SEC filings before making investment decisions.

šŸ“‹ Official Regulatory 10-K / 10-Q SEC Filings

Direct authenticated documentation links to audited SEC database reports for THC.

SEC EDGAR Live Feed
Loading financial data and tables...
šŸ“

SEC Filings (THC)

Ā© 2026 Stock Market Info — Tenet Healthcare Corporation (THC) Financial Profile